InvestorsHub Logo
Post# of 251788
Next 10
Followers 829
Posts 119609
Boards Moderated 14
Alias Born 09/05/2002

Re: DewDiligence post# 178881

Monday, 10/06/2014 10:01:42 AM

Monday, October 06, 2014 10:01:42 AM

Post# of 251788
ACT acquires DRTX for $23/sh in cash + CVR:

http://finance.yahoo.com/news/actavis-acquire-durata-therapeutics-inc-120000538.html

…Actavis will commence a tender offer to acquire all of the outstanding shares of Durata common stock for $23.00 per share in cash, or approximately $675 million in the aggregate, and contingent value rights (CVRs) entitling the holder to receive additional cash payments of up to $5.00 per share if certain regulatory or commercial milestones related to Durata's lead product DALVANCE are achieved.

Excluding the CVR, the buyout premium is 66% and the nominal deal value is $675M.

DRTX’s Dalvance was the answer to an iHub quiz a few months ago (#msg-103497994).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.